New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference

About this update from Alzecure Pharma Ab

[{"type":"text","content":"STOCKHOLM, SE / ACCESS Newswire / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that an abstract about the preclinical project TrkA-NAM ACD137 against osteoarthritis and other severe pain conditions has been accepted for presentation at the international pain conference NeuPSIG 2025, to be held in Berlin, Germany, September 4-6.","length":504,"tagName":"p"},{"type":"text","content":"The abstract, titled Analgesic and anti-inflammatory effects of ACD137, a potent and selective negative allosteric modulator of TrkA , will be presented at NeuPSIG 2025 by Märta Segerdal, Head of Development and Chief Medical Officer at AlzeCure Pharma. Co-authors are Pontus Forsell, Maria Backlund, Veronica Lidell, Azita Rasti, Cristina Parrado-Fernandez, Johan Sandin and Gunnar Nordvall.","length":392,"tagName":"p"},{"type":"text","content":"The results show that the lead drug candidate in the project, ACD137, has potent analgesic effects in several different preclinical pain models. The analgesic effect of ACD137 in the study was as potent as the effect of the anti-NGF antibody Tanezumab, which has demonstrated significant and robust pain relief in several clinical trials. ACD137 achieves its effect by blocking NGF-mediated signaling via TrkA receptors, a biological mechanism with strong genetic, preclinical and clinical validation for its role in pain.","length":522,"tagName":"p"},{"type":"text","content":"These positive preclinical data in models of osteoarthritis, neuropathic pain and nociceptive pain further strengthen previous positive analgesic results obtained with ACD137 and further underline its broad applicability in various severe pain conditions, including osteoarthritis.","length":281,"tagName":"p"},{"type":"text","content":""These data demonstrate that our drug candidate ACD137 is a highly potent and selective TrkA-NAM that exhibits significant analgesic effects in relevant preclinical animal models. Furthermore, this small molecule TrkA-NAM has the potential to avoid some of the side effects observed with anti-NGF antibodies due to a more selective mechanism of action, while maintaining analgesic efficacy," said Pontus Forsell, project leader and Head ...

More updates from Alzecure Pharma Ab